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Controlled trial of twelve versus six courses of chemotherapy in the
treatment of small-cell lung cancer
Report to the Medical Research Council by its Lung Cancer Working Party
Prepared on behalf of the participating members by Professor N.M. Bleehen (Chairman), Mr P.M. Fayers (Statistician), Dr
D.J. Girling (Secretary and Coordinator) and Mr R.J. Stephens (Data Manager).
Summary A total of 497 patients with histologically or cytologically confirmed small-cell lung cancer
were prescribed initial treatment with six courses of etoposide, cyclophosphamide, methotrexate and
vincristine at 3-week intervals. Patients with limited disease (74% of the total) also received radiotherapy
(40Gy in 15 fractions in 3 weeks) to the primary site between courses 2 and 3. At the end of this initial
treatment, 265 patients still in complete or partial response were randomly allocated to six further courses of
maintenance chemotherapy (M series: 131 patients) or to no maintenance chemotherapy (NoM series: 134
patients). Response, as assessed 3 weeks after the second course of initial chemotherapy, was achieved in 85%
of the 264 patients assessed, a complete response in 11%. The median survival period from the date of start
of chemotherapy was 39 weeks; 154 (31%) of the patients were alive at 1 year, 29 (6%) at 2 years and 17
(3%) at 3 years. The patients' general condition and extent of disease pretreatment correlated significantly
with survival. Among the 131 M and 134NoM patients there was no overall survival advantage to either
series (P = 0.27, log rank test), although in 99 patients who had a complete response to initial chemotherapy
as assessed at the time of randomisation there was a suggestion that survival was longer in the M series
(P < 0.05, log rank test), the median survival periods from the date of randomisation being 42 weeks for the
M and 30 weeks for the NoM patients. Maintenance chemotherapy was associated with additional toxicity
and a poorer quality of life as assessed intermittently by clinicians and daily by patients. In conclusion, no
worthwhile clinical advantage was achieved by the policy of continuing chemotherapy beyond six courses,
except possibly in patients with a complete response to the initial six courses.
Small-cell lung cancer is usually highly sensitive to multi-
drug chemotherapy and radiotherapy (reviewed by Aisner et
al., 1983; Greco et al., 1985; Livingston, 1986). Because the
disease is known to metastasise early, many clinicians have
adopted a treatment policy combining these two modalities
in the initial treatment of patients, even when disease at
presentation is apparently limited to the primary site and
regional lymph nodes (MRC Lung Cancer Working Party,
1979). The role of radiotherapy to the tumour and related
lymph nodes additional to chemotherapy remains uncertain:
some series have shown that radiotherapy reduces the
incidence of local recurrence and prolongs survival, but
others suggest that chemotherapy alone gives as good results
(reviewed by Bleehen, 1986). The aims of treatment are to
control the symptoms of disease and to prolong survival as
assessed by median survival time or (more importantly)
survival for 2 years or longer, or by local and metastatic
relapse-free intervals.
The treatment is troublesome to the patient and may be
toxic and it is therefore undesirable to continue treatment
for longer than is necessary. If the tumour responds, a
maximum response, complete or partial (World Health
Organization, 1979), is usually achieved after only two or
three courses of chemotherapy, but it is not known how
much longer treatment should be continued to obtain
maximum sustained therapeutic benefit (reviewed by Greco
et al., 1985). The present multicentre randomised study was
designed to compare 12 against six courses of the same
chemotherapy in the treatment of both limited and extensive
disease, the patients with limited disease also receiving
radiotherapy to the tumour and related lymph nodes after
the second course of chemotherapy.
Methods
Eligibility
Patients aged 75 years or less were eligible if they had
previously untreated, histologically or cytologically proved
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small-cell lung cancer of any extent, normal renal function,
and were able to get out and about, even if activity was
restricted, and to walk over 100 yards along the flat without
dyspnoea (WHO grade 0-2; World Health Organization,
1979), unless poor performance status was due to an
unrelated condition or to a cause, such as inappropriate
ADH secretion, likely to respond to chemotherapy. Patients
were not eligible if they had some other disease contra-
indicating chemotherapy or radiotherapy.
Histological or cytological diagnosis
The diagnosis was made by the histopathologist from the
referring centre according to the WHO classification (World
Health Organization, 1981) on a specimen obtained from
bronchial, pleural, lung, mediastinal or lymph node biopsy,
bronchial brushings, or sputum cytology. The specimens
were later examined by a single reference histopathologist for
confirmation of the cell type.
Pretreatment investigations
The pretreatment investigations included a thorough clinical
examination, a postero-anterior chest radiograph, measure-
ment of the blood haemoglobin and urea and plasma
creatinine concentrations, and total blood white cell and
platelet counts. The extent of disease as assessed on clinical
and radiographic evidence was recorded as either limited to
the soft tissue of one hemithorax, the mediastinum and the
ipsilateral and contralateral scalene and lower cervical lymph
nodes (limited disease), or more extensive than this (extensive
disease).
Initial treatment (all patients)
All patients were prescribed initial treatment with 6 courses
of chemotherapy, each course given on three consecutive
days at 3-week intervals. Etoposide 120mgm-2 was given
by intravenous infusion over 30 min, together with cyclo-
phosphamide 1 gm-2, methotrexate 35 mgm-2 and vincristine
1.3 mgm 2 (maximum dose 2.0mg) by intravenous injection
on day 1. Etoposide 240mgm-2 by mouth or 120 mgm- 2
intravenously was given on days 2 and 3. Patients with
limited disease were also given megavoltage radiotherapy to
a midline dose of 40 Gy in 15 daily fractions over 3 weeks
Br. J. Cancer (1989), 59, 584-590CONTROLLED TRIALS OF SMALL-CELL LUNG CANCER 585
between the second and third courses of chemotherapy,
starting 3 weeks after the second course. It was delivered
through planned portals to the primary site and mediastinal
lymph nodes, the field extending at least from the supra-
sternal notch to 3 cm below the carina and encompassing the
full width of the mediastinum and lung hila.
Allocation to maintenance or no maintenance chemotherapy
Patients in partial or complete response (that is with an
estimated decrease in tumour size of 50% or more (World
Health Organization, 1979)) at the time of the fifth course of
initial chemotherapy were eligible for random allocation
either to six more courses of maintenance chemotherapy (M
series) or to no maintenance chemotherapy (NoM series), the
allocation being stratified for admitting centre, extent of
disease pretreatment and degree of response (partial or
complete) at the time of randomisation. Maintenance chemo-
therapy consisted of the same chemotherapy in the same
dosages as before, but starting 4 weeks after the sixth course of
initial chemotherapy and at intervals of 4 instead of 3 weeks.
Reports and investigations
In addition to a pretreatment report, a report on each
patient was completed at each attendance for treatment, then
monthly up to 12 months and then once every 3 months.
These reports included details of the treatment given, the
response to treatment, adverse reactions encountered,
metastases, the blood haemoglobin concentration and total
white cell and platelet counts. At death, the certified cause
was reported and if an autopsy was done, the findings.
Assessment of quality of life
At each attendance the clinician recorded his assessment of
the patient's overall condition, level of activity and degree of
breathlessness according to the categories shown in Table I.
In addition, the patients themselves completed a daily diary
card (Fayers & Jones, 1983) every evening after their last
meal, recording how they had been feeling during the past
24h, coding their assessments as below.
Table I Condition pretreatment of all 497 patients
Condition
Sex: Male
Age (years):
less than 45
45-54
55-64
65 or more
Extent of disease: Limited
Overall condition:
1. Excellent
2. Good
3. Fair
4. Poor
5. Very poor
Not recorded
Level of physical activity:
1. At work or active retirement
2. Full activity but not at work
3. Out and about, but activity restricted
4. Confined to home or hospital
5. Confined to bed
Not recorded
Degree of breathlessness:
1. Climbs hills or stairs without dyspnoea
2. Walks any distance on flat without dyspnoea
3. Walks over 100 yards without dyspnoea
4. Dyspnoea on walking 100 yards or less
5. Dyspnoea on mild exertion, e.g. undressing
Not recorded
55
243
163
23
2
11
115
154
207
4
0
17
100
162
193
12
3
27
11
50
-34
S
<1
24
32
43
1
0
21
34
41
3
1
Vomiting 1, none; 2, poor appetite; 3, felt sick but wasn't;
4, sick once; 5, sick more than once.
Activity 1, normal work/housework; 2, normal work but
with effort; 3, reduced activity but not confined to home; 4,
confined to home or hospital; 5, confined to bed.
Mood 1, very happy; 2, happy; 3, average; 4, miserable; 5,
very miserable.
Anxiety 1, very calm; 2, calm; 3, average; 4, anxious; 5,
very anxious.
Overall condition 1, very well; 2, well; 3, fair; 4, poor; 5,
very ill.
Results
Patients in the study
Between June 1981 and February 1985, 542 patients were
admitted from 26 centres in the United Kingdom; seven
patients were excluded because they were not eligible and
had been admitted in error and 38 because the reference
histopathologist considered that their histology was not
small-cell lung cancer. There remain 497 patients for
analysis.
Before treatment (Table I) 74% of the patients had limited
disease, the overall condition as assessed by the clinicians
was excellent or good in 61%, the level of physical activity
was normal in 56% and 56% were able to walk any distance
along the flat without dyspnoea.
Initial response and randomisation
The initial response to treatment was assessed from clinical
and radiographic findings alone 3 weeks after the second
course of chemotherapy, that is 6 weeks after the start of
chemotherapy and before any radiotherapy was given. Of
398 patients alive at that time, 264 were assessed. Of the 264,
225 (85%) had a response, 29 (11%) a complete response.
In all, 295 of the 497 patients completed the initial period
of treatment and were still responding, and a further 29
completed but were no longer responding. The remaining
173 did not complete the initial period, the reason being
death in 128, inadequate response in 16, refusal in 16 and
toxicity in 13. Of the 295, 265 (53% of the 497) were
allocated at random to either maintenance (131 patients) or
no maintenance (134 patients) chemotherapy. The remaining
30 patients, all potentially eligible for randomisation, were
not randomised, the reason being toxicity in 13, refusal in six
and continuation of chemotherapy beyond six courses
(without randomisation) in three; for the remaining eight no
reason was given. Of the 265 patients allocated, 196 (74%)
had had limited disease on admission and 99 (37%) had
achieved a complete response as assessed at the time of
randomisation.
Chemotherapy received
During the initial period of treatment (Table II), 278 (56%)
of the 497 patients received their chemotherapy without
modification. A further 156 (31%) had their chemotherapy
modified at the decision of the clinician because of toxicity;
59 (12%) had all their chemotherapy stopped, and the
remaining four (1%) never started chemotherapy: three died
and the fourth declined all treatment.
Of the 131 patients allocated to receive maintenance
chemotherapy, 46 (35%) received it without modification. A
further 21 (16%) had their maintenance chemotherapy modi-
fied at the decision of the clinician because of toxicity, 31
(24%) had all their maintenance chemotherapy stopped and
the remaining 33 (25%) never started maintenance chemo-
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Table II Chemothera;
c
Chemotherapy
Received without modification
All six courses
Until no longer responding
Until death
Total
Modified because of toxicity
One or more courses delayed
One or more drugs withdrawn
Dosages reduced
Total
All drugs stopped
Toxicity
Patient declined to continue
Clinician decided not to continue
Total
Never started
Total patients
shortly after randomisation (five of
their clinician decided it would be i
Of the total 497 patients, 159 rece
for relapse, this being chemothera
therapy alone in 120 and both in 2
Survival
Follow-up is complete for all 497 pa
the date of start of chemotherapy (c
for the four patients who never sta
survival curves from the date of sta
according to the level of physical,
graded in Table I). Survival was sig
patients with a better grade of acti
test) and the difference was largely
py received deaths in patients graded 3 or 4. Indeed, six (2%) of the
Initial Maintenance patients graded 1 or 2 died during the first 3 weeks
-hemotherapy chemotherapy compared with 26 (12%) graded 3 or 4 (P < 0.001). The
median survival period from the date of start of chemo- No. 0 No. 00 therapy (Table III) was 39 weeks; 154 (31%) of the patients
were alive at 1 year, 29 (6%) at 2 years and 17 (3%) at 3
157 22 years. To date, 12 of 452 assessable are alive at 4 years, and
30 16 six of 287 at 5 years.
91 8 There is no statistically significant difference between
278 56 46 35 survival in the M and NoM series during 3 years from
randomisation (P = 0.27, log rank test) (Figure 2), the
113 13 median survival periods from the date of randomisation
24 6 being 35 weeks (M) and 29 weeks (NoM). Because 25% of
156 31 21 16 the M patients received no maintenance chemotherapy, the small separation between the survival curves could have
represented an underestimate of its true effect. Survival was
31 3 therefore studied in the 91 M patients alive at 6 months after 23 22 randomisation (who could have received all six courses). Of
59 12 31 24 the 91, 15 received no maintenance chemotherapy, five
received one course, and 10, 12, 8, 12 and 29 received two,
4 1 33 25 three, four, five and six courses, respectively. No evidence of
497 100 131 100 a trend between the duration of survival and the amount of
maintenance chemotherapy actually received was found,
them dying) and in three further evidence that prolonging chemotherapy beyond six
inappropriate. treatment
courses did not, in general, influence survival. nivedadditionala treatme.t Separate analyses of four subgroups of the 265 ran-
ivedaddlitional tratmen domised patients were made, namely the 196 with limited,
ipy alone in 16 radio- the 69 with extensive disease pretreatment, the 166 with !3 patients. partial and the 99 with complete response to chemotherapy
at the time of randomisation. The only subgroup in which
there was a suggestion that maintenance chemotherapy
[tients up to 3 years from influenced survival was patients who had had a complete
wr from the date of entry response, among whom it prolonged survival (P < 0.05,
rted chemotherapy). The logrank test). The median survival periods from the date of
rt are shown in Figure 1 randomisation within this subgroup were 42 weeks for the M
activity pretreatment (as and 30 weeks for the NoM patients. Thus there may possibly
gnificantly longer for the be a small advantage from continuing chemotherapy beyond
ivity (P < 0.001 logrank six courses in patients still showing complete response at the
accounted for by early end of their initial six courses of treatment.
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Figure 1 Survival from date of start of chemotherapy according
to the level of physical activity of the patients pretreatment.
Figure 2 Survival from the date of start of chemotherapy and
from the date of allocation in the 131 M and 134 NoM patients.
Table III Survival from date of start of chemotherapy according to the level of physical activity
pretreatment
Patients alive at:
Level of Median 1 year 2 years 3 years
physical Patients survival
activity assessed (weeks) No. % No. % No. %
I or 2 269 44 96 36 22 8 14 5
3 or 4 211 33 55 26 7 3 3 1
Not assessed 17 - 3 18 0 0 0 0
Total 497 39 (37-43) 154 31 (27-35) 29 6 (4-8) 17 3 (2-5)
Figures in parentheses are 95% confidence limits.
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Prognostic factors
A proportional hazards model (Cox, 1972) was used to
determine the factors relating to survival for (1) all patients
and (2) those surviving long enough to be eligible for the M/
NoM randomisation, whether or not they were randomized.
The pretreatment factors considered in all patients were sex,
age, extent of disease, haemoglobin concentration, white cell
and platelet counts, height, weight, surface area, general
condition, level of physical activity and degree of breath-
lessness. The most important factor was general condition
(P<0.001) but adding extent of disease (P<0.005)
improved the prognostic discrimination.
The median time of randomisation was 145 days from the
date of start of chemotherapy and 369 patients (74% of the
original 497) who survived to this time were included in the
second analysis. All the above factors were considered, along
with initial response to treatment and, at the time of
randomisation, weight, haemoglobin concentration, white
cell and platelet counts, general condition, level of physical
activity and degree of breathlessness, and the main adverse
reactions. The most important factor was response to
treatment (P < 0.001), but adding extent of disease pre-
treatment (P < 0.001) and level of physical activity at time
of randomisation (P < 0.005), improved the prognostic
discrimination.
Even allowing for the above prognostic factors, there was
no significant benefit from maintenance chemotherapy.
Time of death related to chemotherapy
There were 95 patients who died within 4 weeks after the
start of a course of initial or maintenance chemotherapy. Of
these, 13 died in the first week after the start of the course,
55 in the second, 14 in the third and 13 in the fourth week
(P < 0.001, X2 test). The 95 included 41 who died within 4
weeks after the start of the first course of initial chemo-
therapy. Of the 41, nine died in the first, 22 in the second,
five in the third and five in the fourth week. There was thus
an unexpectedly high risk of death during the second week
after the start of a course of chemotherapy.
Cause of death
Among the 480 patients who died during the 3 years,
carcinoma was the certified underlying cause of death in all
except eight, in whom it was myocardial infarction in four,
and in the remaining four cerebrovascular accident, ruptured
aortic aneurysm, perforated gastric ulcer and broncho-
pneumonia (in the absence of any evidence of residual
cancer). Of the 480 patients, 312 (65%) had evidence of
persistence or recurrence of tumour at the primary site. Of
these, 228 also had distant metastases. For only 25 of the
312 and 22 of the 228 did this evidence include autopsy
findings. In all, 378 (79%) of the 480 patients had evidence
of distant metastases at the time of death.
It was thought that treatment may have caused or has-
tened death in 15 (3% of 497) patients, the initial chemo-
therapy in 11 and maintenance chemotherapy in four. Seven
of the 15 died with septicaemia, four with broncho-
pneumonia, one with marrow depression and one with
radiation pericarditis, and two died suddenly and unexpec-
tedly within 10 days of a course of chemotherapy.
Metastases in patients with limited disease on admission
Table IV presents an analysis of the first appearance of
distant metastases from the time of randomisation to main-
tenance or no maintenance chemotherapy. There was a
suggestion that brain metastases may have been slightly
delayed in the M series but this is not statistically significant
(P = 0.22, log rank test). The findings for the other sites and
for metastases at any site were very similar for the two
series. These observations provide further evidence that
prolonging chemotherapy beyond six courses brought no
worthwhile therapeutic benefit.
Table IV Occurrence ofdistant metastases from date of randomisa-
tion in 78 M and 82 NoM patients with no evidence of distant
metastases at time of randomisation
Cumulative percentage ofpatients with
distant metastases at the following
times from randomisation
6 months 12 months 24 months
Site of
metastases M NoM M NoM M NoM
Liver 15 12 27 26 33 29
Brain 9 23 27 35 32 39
Bone 18 16 26 27 28 29
Other 8 10 13 12 14 15
Any site 36 40 64 62 72 68
Table V Main adverse reactions other than alopecia reported
during the initial period of chemotherapy
Patients
Reaction No. %
Nausea without vomiting 71 14
Vomiting 233 47
Diarrhoea 43 9
Dysphagia 16 3
Mouth ulcers 55 11
Rash 30 6
Paraesthesia 53 11
Peripheral neuropathy 28 6
Cystitis 4 1
Haematological (WHO grade 2 or worse)a
Total 176 (223) 35 (45)
Anaemia (Hb 9.4gdl-' or less) 105 (118) 21 (24)
Leucopenia (WBC 2.9 x 103 mm-3 or less) 100 (148) 20 (30)
Thrombocytopenia (platelets 74 x 103 mm3
or less) 20 (43) 4 (9)
Total patients with reactions 410 82
Total patients 497 100
aPatients with haematological toxicity at routine assessments are
shown. The figures in parentheses include patients with toxicity at all
assessments, whether routine or not.
Adverse reactions
The main adverse reactions, other than alopecia, that were
reported during the initial period of chemotherapy are
shown in Table V. Haematological toxicity of WHO grade 2
(World Health Organization, 1979) or worse was reported at
routine assessments immediately before a course of chemo-
therapy in 35% of patients. Additional blood counts were
done, however, if there was concern about a patient's
progress. When these additional results are included, haema-
tological toxicity was reported in 45% of the patients. In
addition, 17 (3%) patients had episodes of septicaemia
attributed to drug-induced leucopenia and 98 (20%) were
given blood transfusions for anaemia.
During the period after randomisation, adverse reactions
were reported in 80 (61%) of the 131 M compared with 16
(12%/M) of the 134 NoM patients (P < 0.0001). In the M
series, nausea without vomiting was reported in 45 (34%),
Table VI Effect of radiotherapy on platelet counts in 107 patients
who received radiotherapy (RT) and 73 who did not (No RT),
limited to patients who had platelet counts available at all five
assessments
Mean platelet count
(1000mm-3)
Assessment + 1.96 standard error
RT No RT RT No RT
Before course 1 Before course 1 328 (304-352) 369 (332-407)
Before course 2 Before course 2 420 (387-453) 454 (401-506)
At start of RT Before course 3 414 (380-448) 452 (407-498)
At end of RT Before course 4 215 (119-230) 438 (396-480)
Before course 3 Before course 5 262 (245-280) 410 (373-446)588 REPORT TO THE MEDICAL RESEARCH COUNCIL
vomiting in 40 (31%), paraesthesiae in 17 (13%), peripheral
neuropathy in 10 (8%) and mouth ulcers in nine (7%). The
corresponding results for the NoM series were four (3%),
three (2%), none, two (1%) and one (1%). Septicaemia was
reported in six of the M compared with one of the NoM
patients. Thus, toxicity was considerably reduced by stop-
ping chemotherapy after six courses.
There were 116 patients who received radiotherapy
between the second and third courses of chemotherapy and
who had their platelet counts measured at all five of the
routine assessments before the first, second and third courses
of chemotherapy and at the start and end of radiotherapy.
Their platelet counts were compared (Table VI) with those
of patients who did not receive radiotherapy but who had
their platelet counts measured at all five of comparable
routine assessments, namely before the first five courses of
chemotherapy. The mean platelet counts were considerably
reduced at the end of radiotherapy and 3 weeks afterwards
but were unchanged at comparable assessments in the
patients who did not receive radiotherapy. There were no
equivalent differences attributable to radiotherapy in the
white cell counts or haemoglobin concentrations (details not
shown).
Quality of life
The findings on quality of life are to be reported and
discussed in detail elsewhere. The main findings during the
M/NoM comparison are summarised here.
Clinicians' assessments The overall condition of the
patients, their level of physical activity and degree of breath-
lessness as recorded by the clinicians when the patients
allocated to the M/NoM comparison attended for assess-
ment at 3 weeks, 6 weeks, 3 months and 6 months from the
date of randomisation are shown in Table VII. The propor-
tions were similar for the two series initially, but by 6
months there was a clear advantage to the NoM patients,
higher proportions being assigned the better categories and
lower proportions the worse categories for all three assess-
ments, namely overall condition (P < 0.05), level of physical
activity (P < 0.01) and degree of breathlessness (P < 0.05).
Compliance in the use of the daily diary cards The intention
was that diary cards should be completed daily by the
patients from admission until approaching death. From the
date of randomisation, 94 (35%) of the 265 patients returned
no cards at all, 35 (13%) returned cards covering 1-25% of
their survival time or of 6 months from randomisation
(whichever was shorter), 31 (12%) 26-50% of this period
and 105 (40%) 51-100%.
Quality of life as recorded by patients The quality of life
during the 6-week period starting 3 weeks after the sixth
course of chemotherapy as recorded by patients on their
daily diary cards is expressed, in Table VIII, in terms of the
percentage of patient-days for each category. This analysis is
based on the 64 M and 45 NoM patients who provided at
Table VII Clinicians' assessments of overall condition, level of activity, and degree of breathlessness from allocation to
maintenance or no maintenance chemotherapy
Percentage of
3 weeks
patients at the following times from date of
allocation
6 weeks 3 months 6 months
Assessment
Overall condition:
1. Excellent
2. Good
3. Fair
4. Poor
5. Very poor
Level of physical activity:
1. At work or active retirement
2. Full activity but not at work
3. Out and about but activity restricted
4. Confined to home or hospital
5. Confined to bed
Degree of breathlessness:
1. Climbs hills or stairs without dyspnoea
2. Walks any distance on flat without dyspnoea
3. Walks over 100 yards without dyspnoea
4. Dyspnoea on walking 100 yards or less
5. Dyspnoea on mild exertion, e.g. undressing
Total patients assessed
Total patients alive
M NoM M NoM M NoM M NoM
15
52
28
4
0
18
40
32
10
0
35
22
29
10
3
16
42
33
8
1
22
30
39
8
1
36
29
21
12
2
13
53
32
1
0
16
40
39
5
0
26
34
25
14
1
21
49
19
7
4
25
38
25
6
6
33
30
17
16
4
10
48
34
9
0
21
28
41
10
0*
31
28
23
11
7
23
47
17
10
2
30
23
33
10
3
31
37
21
8
2
14
28
41
13
4
18
23
41
14
4
23
28
28
13
9
26
43
13
13
4
37
27
27
8
2
47
16
25
8
4
92 92 77 72 103 86 71 53
128 133 127 133 119 114 91 73
Table VIII Patients' assessments of quality of life during the 6-week period starting 3 weeks
after the sixth course of chemotherapy, based on the 64 M and 45 NoM patients with at least
50% of relevant data available
Percentage ofpatient-days
Category Overall
recorded Vomiting Activity Mood Anxiety condition
on diary
carda M NoM M NoM M NoM M NoM M NoM
1 78 91 19 30 8 15 6 19 11 20
2 10 4 19 28 30 35 39 39 33 45
3 5 3 41 37 51 39 43 33 45 30
4 3 0 18 5 9 11 10 10 10 6
5 4 1 3 0 1 0 3 0 1 0
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least 50% of the relevant data. The proportion of patient-
days for the two best categories combined (categories 1 and
2) was higher for the NoM series for all five factors, and for
the two worst categories combined (categories 4 and 5) was
higher for the M series for all factors except mood.
Thus, quality of life from the time of the M/NoM
randomisation was better for the NoM patients, as assessed
both intermittently by the clinicians and daily by the
patients, further reason for not continuing chemotherapy
beyond six courses.
Discussion
This study has shown that when the present chemotherapy
regimen of etoposide, cyclophosphamide, methotrexate and
vincristine is used in the treatment of limited or extensive
small-cell lung cancer, no important overall therapeutic
advantage is to be gained from a policy of continuing
chemotherapy beyond six courses in patients still showing
response at that time. Of 497 eligible patients admitted to
the study, 265 completed their initial six courses of chemo-
therapy and were randomised to a further six courses of
maintenance chemotherapy (131 patients) or to no further
chemotherapy (134 patients) until relapse, the randomisation
being stratified for admitting centre, extent of disease pre-
treatment and degree of response at the time of randomisa-
tion. In a straight comparison between the two groups of
patients, there was no evidence of a difference in survival
during 3 years of follow-up (P = 0.27, log rank test) and
control of the primary cancer and of distant metastases was
very similar. Of the 131 patients allocated to receive main-
tenance chemotherapy, only 35% received it without modifi-
cation. A further 16% had it modified because of toxicity
and 24% had it stopped; the remaining 25% never started.
Nevertheless, there was no evidence of a trend between the
duration of survival and the amount of maintenance chemo-
therapy actually received.
In analyses of subgroups of patients, there was a sugges-
tion that maintenance chemotherapy may have prolonged
survival among 99 patients with a complete response to their
initial chemotherapy as assessed at the time of randomisa-
tion (P<0.05, log rank test). This finding should not,
however, be regarded as conclusive, because comparing
subgroups increases the likelihood of obtaining such a
difference by chance (Simon, 1982). Also, in the 91 patients
(complete and partial responders) who were allocated to
maintenance chemotherapy and who were still alive 6
months later, there was again no evidence of a trend between
duration of survival and amount of maintenance chemo-
therapy actually received.
During the period of chemotherapy, deaths were not
evenly distributed during and between courses. They were
most likely to occur during the second week after the date of
start of the last course before death, that is, when the white
cell count was likely to have been at its lowest. This finding
is similar to that observed by Souhami and his colleagues
who also found that such deaths were more likely to occur
in patients with other unfavourable prognostic factors
present pretreatment, especially poor performance status,
hepatomegaly, and abnormal liver function tests (Souhami et
al., 1988). In the present study, 26 of 32 assessable deaths
during the first 3 weeks of the study occurred in patients
with a poor performance status on admission (activity grade
3 or 4). Souhami and his colleagues (personal communica-
tion) have shown that this high risk of early death in
patients with a poor performance status can be greatly
reduced by giving antibiotics prophylactically during the
early weeks of chemotherapy. In the present study such
prophylaxis was left to the individual-clinician to decide.
Several drug schedules have been used in attempts to
improve the results of therapy for small-cell lung cancer.
They include alternating non-cross-resistant combinations,
very high dose chemotherapy with autologous marrow
rescue, regimens of alternating chemotherapy and radio-
therapy, and maintenance chemotherapy after an initial
induction course using either the same or different drugs
(reviewed by Aisner et al., 1983; Greco et al., 1985;
Livingston, 1986). There is little if any evidence for any
major improvement in survival as a result of these treat-
ments compared with the more conventional ones, except in
some small non-randomised studies.
The present study solely considers the duration of conven-
tional treatment with the same combination chemotherapy
throughout. Three other studies have addressed this same
question. In a CALGB study of 258 patients (Maurer et al.,
1980), it was reported that maintenance chemotherapy signi-
ficantly prolonged survival in patients with limited disease,
with 33% of the patients alive at 24 months compared with
9% who did not receive maintenance chemotherapy. How-
ever, this was a complicated study which included three
separate randomisations; one limb of the chemotherapy
schedule was abandoned during the trial, and patients were
randomised to the maintenance and no-maintenance series
after achieving a complete response to six courses of induc-
tion chemotherapy. Only 46 patients with limited disease
achieved a complete response and were eligible for randomis-
ation. The results have also been questioned on the basis of
whether the patients in fact received adequate induction
therapy (Greco et al., 1985).
In another study of 309 patients conducted by the
Midland Small Cell Lung Cancer Group (Cullen et al.,
1986), 93 patients who achieved a complete or good response
to induction chemotherapy with six courses of vincristine,
doxorubicin and cyclophosphamide were randomised to a
further eight courses of maintenance chemotherapy or to no
further chemotherapy until relapse. Maintenance chemo-
therapy prolonged survival in the 61 patients with extensive
disease on admission (P = 0.006, logrank test), the median
survival times being 372 compared with 259 days. However,
this survival difference was largely, although not entirely,
accounted for by differences in performance status and
response to induction chemotherapy between the two series.
Moreover, in the 32 patients with limited disease, survival
was longer in the no maintenance series, although this
difference was not statistically significant.
A third study (Harper et al., 1987) reports on a total of
610 evaluable patients with limited or extensive disease
initially. They were randomly assigned to eight or four
courses of cyclophosphamide, vincristine and etoposide and
there was a second randomisation to further chemotherapy
with doxorubicin and methotrexate or to symptomatic treat-
ment alone at the time of relapse. There was a small benefit
from more prolonged chemotherapy, the median survival
times being 39 and 32 weeks (P = 0.085), and the relapse-
free intervals 31 and 23 weeks (P < 0.0002). However, when
chemotherapy on relapse was given, the difference was
eliminated.
These three studies, together with the one currently
reported, do show some evidence of benefit to be gained
from prolonging treatment beyond a short induction period
in some patients. Other studies using different drugs in the
induction and maintenance phases have not shown any
appreciable benefit (Woods et al., 1984; Feld et al., 1981,
1984). The question remains as to whether any advantage at
all would be seen following more effective short-term regi-
mens initially or on relapse. End-points must not only
include short-term survival as expressed by median survival
times, but proportions of long-term survivors at 2 and 3
years as in the present study.
The quality of survival is also important. In the present
study, potentially troublesome adverse effects were reported
in 61% of the patients during maintenance chemotherapy
compared with only 12% during the same period in those
who were allocated to no further chemotherapy until relapse
(P < 0.0001), the main types being nausea, vomiting, paraes-590 REPORT TO THE MEDICAL RESEARCH COUNCIL
thesia, peripheral neuropathy and mouth ulcers. Thus,
patients can be spared a considerable amount of unpleasant
and potentially serious toxicity if the policy is to give no
more than six courses of chemotherapy in primary
treatment.
The quality of life of the patients was also recorded
intermittently by the clinicians and daily by the patients
using a diary card during the- period of maintenance or no
maintenance chemotherapy. According to both the clinicians'
assessments, based on overall condition, level of physical
activity and degree of breathlessness, and the patients'
assessments, based on the severity of nausea and vomiting,
level of physical activity, mood, degree of anxiety and
overall condition, the quality of life was better for patients
allocated not to receive maintenance chemotherapy.
In conclusion, no clear evidence has emerged from this
study that survival can be prolonged to a clinically worth-
while extent by a policy of continuing chemotherapy beyond
an initial six courses. Also, continuing chemotherapy beyond
six courses increases the amount of unpleasant and poten-
tially serious toxicity and adversely affects the quality of
patients' lives. In view of the somewhat equivocal findings in
the subgroup of patients who had a complete response to
their initial chemotherapy, and the findings by Cullen et al.
(1986) and Harper et al. (1987) that maintenance chemo-
therapy prolonged survival in some groups of patients,
further studies on the optimum duration of chemotherapy in
the treatment on small-lung cancer are required. The MRC
Lung Cancer Working Party is currently comparing six
versus three courses of the regimen used in the study
reported here.
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